Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-20

Hi @killfeather

Can you (or anyone else?) point me to news confirming "...squid sensor detection..."?

In my mind, this is the missing piece of info.

We've been told that the imaging agent is well tolerated, no safety issues and "...is capable of reaching the lymph nodes..." (see https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP6we1zxaZqfVhke92GA%3D%3D).

We've also been told "...From the interim assessment showing that the nanoparticles can reach the target lymph nodes we believe we are one step closer to demonstrating that targeted magnetic nanoparticles can be used to non-invasively find and detect the presence of cancer..." (see https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP6gq%2ByheZqfVhke92GA%3D%3D). Of course, this statement could relate equally to MRI or MRX - the lack of clarity is what concerns me.

I've been waiting for confirmation that the injectable is performing as expected using MRX / squid detection to produce the functional image that is the 'printer' in our printer and ink model, but I've not seen anything to date.

The fact that the imaging agent is reaching the lymph nodes may well have been confirmed by histopathology post resection, as this is part of the study design. Whether the imaging agent is actually working to produce a fuctional image (as opposed to an MRI contrast agent) is, to my knowledge, unconfirmed at this time. I also feel as though the language being adopted in communications is now leaning towards MRI contrast agent and away from MRX.

I dearly hope to be proven wrong.

Cheers

Densy